Globus Medical Inc. Class A Common Stock (GMED)
Stock · NYSE · Health Care
$76.69as of 10/16/2026
Price chart
Active signals
GMED Signal Track Record
How signals performed across all stocks →What GMED's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 32 | +0.4% | 53% | September 18, 2026 |
| Bollinger Band Breakout | 25 | +1.2% | 60% | October 5, 2026 |
| Bollinger Band Breakdown | 21 | -1.5% | 43% | September 3, 2026 |
| 200-Day Moving Average TouchActive now | 16 | -2.1% | 38% | August 11, 2026 |
| Any 20-session window (baseline) | +0.4% | 52% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About GMED
Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products comprising traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices; treatment options for motion preservation technologies consisting of dynamic stabiliza…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Employees
- 6,000
- Website
- www.globusmedical.com/
Fundamentals
- 1-day range
- $77.05$79.28
- Market cap
- $11.01B
- P/E (trailing)
- 19.14
- P/E (forward)
- 14.60
- EPS (trailing)
- $3.91
- Dividend yield
- —
- Beta
- 0.97
- Avg. volume
- 1.45M
How Globus Medical Inc. Class A Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 24, 2026 · via SEC EDGAR / Finnhub
Forecasts
13 analyst ratings
Globus Medical Inc. Class A Common Stock Competitors
Chosen by industry and closest market cap.
- GMEDGlobus Medical Inc. Class A Common Stock$76.71▼ 2.70%Market cap $11.01BP/E 19.14$56.96$101.4
- GKOSGlaukos Corporation Common Stock$164.84▼ 0.46%Market cap $10.09BP/E —$73.16$191.62
- PODDInsulet Corporation Common Stock$141.1▲ 1.68%Market cap $9.65BP/E 25.40$126.4$354.88
- BAXBaxter International Inc. Common Stock$25.28▼ 1.86%Market cap $13.96BP/E —$15.73$30
- TFXTeleflex Incorporated Common Stock$130.43▲ 1.72%Market cap $6.15BP/E —$100.18$145
- STVNStevanato Group S.p.A. Ordinary Shares$18.9▼ 1.82%Market cap $6.14BP/E 34.82$12.89$27.99
- MMSIMerit Medical Systems Inc. Common Stock$89.2▼ 0.41%Market cap $5.24BP/E 36.33$59.74$94.75
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| GMED Globus Medical Inc. Class A Common Stock | $11.01B | 19.14 | $76.71 | ▼ 2.70% | $56.96$101.4 |
| GKOS Glaukos Corporation Common Stock | $10.09B | — | $164.84 | ▼ 0.46% | $73.16$191.62 |
| PODD Insulet Corporation Common Stock | $9.65B | 25.40 | $141.1 | ▲ 1.68% | $126.4$354.88 |
| BAX Baxter International Inc. Common Stock | $13.96B | — | $25.28 | ▼ 1.86% | $15.73$30 |
| TFX Teleflex Incorporated Common Stock | $6.15B | — | $130.43 | ▲ 1.72% | $100.18$145 |
| STVN Stevanato Group S.p.A. Ordinary Shares | $6.14B | 34.82 | $18.9 | ▼ 1.82% | $12.89$27.99 |
| MMSI Merit Medical Systems Inc. Common Stock | $5.24B | 36.33 | $89.2 | ▼ 0.41% | $59.74$94.75 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Globus Medical Q2 2026 Earnings Call Transcriptbenzinga · 10/12/2026
- Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing DealYahoo · 10/9/2026
- ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/YYahoo · 10/9/2026
- Reasons to Hold Veeva Systems Stock in Your Portfolio for NowYahoo · 10/9/2026
- Is it the Right Time to Hold TNDM Stock in Your Portfolio?Yahoo · 10/9/2026
- Here's Why You Should Retain DaVita Stock in Your Portfolio for NowYahoo · 10/9/2026
- Is it the Right Time to Add Phibro Stock to Your Portfolio?Yahoo · 10/8/2026
- Smith+Nephew Launches CARTIHEAL Implant Across Key European MarketsYahoo · 10/8/2026
- Reasons to Retain Hims & Hers Stock in Your Portfolio for NowYahoo · 10/8/2026
Insider Activity
Insider Actions →- TOBIN JAMES R · September 15, 2026 · Option Exercise15.0K @ $53.75
- TOBIN JAMES R · September 15, 2026 · Sale30.0K @ $74.58
- Stephen T. Zarrilli · August 18, 2026 · Option Exercise25.0K @ $53.27
- Stephen T. Zarrilli · August 18, 2026 · Sale25.0K @ $87.04
- David D. Davidar · July 27, 2026 · Gift2.5K
- David D. Davidar · June 5, 2026 · Option Exercise25.0K @ $26.27
- David D. Davidar · June 5, 2026 · Sale25.0K @ $80.76
- Ann D. Rhoads · June 4, 2026 · Option Exercise25.0K @ $26.27
Institutional Ownership
March 31, 2026
- Total shares held
- 101.10M
- Total value held
- $8.36B
- Institutional holders
- 593
- Unknown10.50M
- Unknown7.62M
- Unknown5.03M
- Unknown4.32M
- Unknown3.59M
- Unknown3.06M
- Unknown2.31M
- Unknown2.11M
- Unknown2.03M
- Unknown2.01M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
RBC Lowers Globus Medical Price Target to $85
RBC Capital has lowered its price target for Globus Medical to $85 while maintaining an Outperform rating. This move comes as the company navigates industry challenges, with recent attention on how medical device firms are using generative AI to manage costs and operations. The stock is currently trading below the average analyst target of $100.92, reflecting a cautious outlook from some investors despite the firm's positive stance.
RBC Lowers Globus Medical Price Target to $85. RBC Capital has lowered its price target for Globus Medical to $85 while maintaining an Outperform rating. This move comes as the company navigates industry challenges, with recent attention on how medical device firms are using generative AI to manage costs and operations. The stock is currently trading below the average analyst target of $100.92, reflecting a cautious outlook from some investors despite the firm's positive stance.